Companies in #RNA Interference (siRNA) Therapeutics
Found 1 company operating in this sector.
TransCode Therapeutics is a clinical-stage oncology company developing a pipeline of RNA-targeted therapeutics using its proprietary TTX (Therapeutic Targeting and Transport) nanoparticle delivery platform, which is designed to enable systemic delivery of siRNA, antisense, and other oligonucleotide payloads to metastatic tumors. The lead program, TTX-MC138, is being studied in metastatic cancer, with Phase 1a completion announced in June 2026 (no DLTs, durable disease stabilization) and a Phase 2a trial in ctDNA-positive colorectal cancer initiated in May 2026.